Primary Care

Interventional Cardiology

Questions discussed in this category

How soon after an elective, uncomplicated coronary intervention would you feel comfortable having a patient travel by air?

3 Answers available

What is your preferred monotherapy antiplatelet agent to continue after completion of DAPT post-PCI for patients with stable ischemic heart disease?

Would coronary disease anatomy influence your selection of which type of antiplatelet agent to continue?

6 Answers available

What is your preferred duration for triple therapy post-PCI in patients on systemic anticoagulation?

3 Answers available

Following completion of antiplatelet monotherapy (i.e., Plavix) plus oral anticoagulation in patients with AFib post-PCI, would you favor continuing antiplatelet therapy + OAC, switching from Plavix to aspirin and continuing OAC, or stopping antiplatelet therapy and continuing OAC?

3 Answers available

Do you favor aspirin or P2Y12 inhibitor monotherapy following completion of 12 months of DAPT post-PCI in patients with elevated bleeding risk?

5 Answers available

What is your approach to correlating stenotic lesions on coronary angiography to magnitude of decline in LV systolic function or cardiomyopathy severity when deciding to intervene or medically manage stable ischemic heart disease as an outpatient?

1 Answer available

What is a reasonable duration of time for dual anti-platelet therapy in patients who have undergone placement of a covered coronary stent?

1 Answer available

Is there emerging and compelling enough evidence to maintain patients on P2Y12i monotherapy (in lieu of aspirin) following completion of DAPT?

1 Answer available

Papers discussed in this category

JAMA Cardiol, 2022 Nov 01

Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.

Circulation, 2019 Jan 29

Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation.

American heart journal, 2015-04

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).

The New England journal of medicine, 2019-04-18

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.

Related Topics in Primary Care